Effect of Remdesivir vs Standard Care on Clinical Status at 11 Days in Patients With Moderate COVID-19: A Randomized Clinical Trial

IMPORTANCE: Remdesivir demonstrated clinical benefit in a placebo-controlled trial in patients with severe coronavirus disease 2019 (COVID-19), but its effect in patients with moderate disease is unknown. OBJECTIVE: To determine the efficacy of 5 or 10 days of remdesivir treatment compared with stan...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:JAMA
Autors principals: Spinner, Christoph D., Gottlieb, Robert L., Criner, Gerard J., Arribas López, José Ramón, Cattelan, Anna Maria, Soriano Viladomiu, Alex, Ogbuagu, Onyema, Malhotra, Prashant, Mullane, Kathleen M., Castagna, Antonella, Chai, Louis Yi Ann, Roestenberg, Meta, Tsang, Owen Tak Yin, Bernasconi, Enos, Le Turnier, Paul, Chang, Shan-Chwen, SenGupta, Devi, Hyland, Robert H., Osinusi, Anu O., Cao, Huyen, Blair, Christiana, Wang, Hongyuan, Gaggar, Anuj, Brainard, Diana M., McPhail, Mark J., Bhagani, Sanjay, Ahn, Mi Young, Sanyal, Arun J., Huhn, Gregory, Marty, Francisco M.
Format: Artigo
Idioma:Inglês
Publicat: American Medical Association 2020
Matèries:
Original Investigation
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC7442954/
https://ncbi.nlm.nih.gov/pubmed/32821939
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1001/jama.2020.16349
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars